Abstract PR010: <i>CDK12</i> loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality
Jean C. Tien(University of Michigan), Arul M. Chinnaiyan(Howard Hughes Medical Institute), Yuping Zhang(University of Michigan), Jianzhang Yang(Jinan University), Xiao Ming Wang(Chinese Academy of Agricultural Sciences), Rachel Brough(Institute of Cancer Research), Jonathan Chou(UCSF Helen Diller Family Comprehensive Cancer Center), Sanjana Eyunni(University of Michigan), Xuhong Cao(Howard Hughes Medical Institute), James Neiswender(Institute of Cancer Research), Marcin Cieślik(University of Michigan), Rahul Mannan(University of Michigan), Estefanía Labanca(The University of Texas MD Anderson Cancer Center), Yi Bao(Stevens Institute of Technology), Yu Chang(University of Michigan), Stephen J. Pettitt(Gene Therapy Laboratory), Christopher J. Lord(Institute of Cancer Research), Yuzhuo Wang(BC Cancer Agency), Xiaoju Wang(Shanxi Agricultural University), Yunhui Cheng(University of Michigan), Caleb Cheng(University of Michigan), Ke Ding(China Pharmaceutical University), Abbey Todd(University of Michigan), Palak Shah(CVPath Institute)
Cited by 0
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k